vs
Esperion Therapeutics, Inc.（ESPR）与Riley Exploration Permian, Inc.（REPX）财务数据对比。点击上方公司名可切换其他公司
Esperion Therapeutics, Inc.的季度营收约是Riley Exploration Permian, Inc.的1.7倍（$168.4M vs $97.3M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs -5.3%），过去两年Esperion Therapeutics, Inc.的营收复合增速更高（10.6% vs -1.2%）
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
Riley Exploration Permian, Inc.是一家独立能源企业，专注于美国得克萨斯州与新墨西哥州境内的二叠纪盆地，开展原油、天然气及天然气凝析液的勘探、开发与生产业务，主打低成本陆上储备开发，为北美市场供应稳定能源产品。
ESPR vs REPX — 直观对比
营收规模更大
ESPR
是对方的1.7倍
$97.3M
营收增速更快
ESPR
高出149.0%
-5.3%
两年增速更快
ESPR
近两年复合增速
-1.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $168.4M | $97.3M |
| 净利润 | — | — |
| 毛利率 | — | — |
| 营业利润率 | 50.6% | 26.9% |
| 净利率 | — | — |
| 营收同比 | 143.7% | -5.3% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $0.32 | $4.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESPRREPX
| Q4 25 | $168.4M | $97.3M | ||
| Q3 25 | $87.3M | $106.9M | ||
| Q2 25 | $82.4M | $85.4M | ||
| Q1 25 | $65.0M | $102.5M | ||
| Q4 24 | $69.1M | $102.7M | ||
| Q3 24 | $51.6M | $102.3M | ||
| Q2 24 | $73.8M | $105.4M | ||
| Q1 24 | $137.7M | $99.7M |
净利润ESPRREPX
| Q4 25 | — | — | ||
| Q3 25 | $-31.3M | $16.3M | ||
| Q2 25 | $-12.7M | $30.5M | ||
| Q1 25 | $-40.5M | $28.6M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-29.5M | $25.7M | ||
| Q2 24 | $-61.9M | $33.5M | ||
| Q1 24 | $61.0M | $18.8M |
营业利润率ESPRREPX
| Q4 25 | 50.6% | 26.9% | ||
| Q3 25 | -11.4% | 27.0% | ||
| Q2 25 | 8.6% | 33.7% | ||
| Q1 25 | -34.0% | 48.3% | ||
| Q4 24 | -6.4% | 31.2% | ||
| Q3 24 | -31.0% | 17.1% | ||
| Q2 24 | 3.5% | 50.9% | ||
| Q1 24 | 52.5% | 50.7% |
净利率ESPRREPX
| Q4 25 | — | — | ||
| Q3 25 | -35.9% | 15.3% | ||
| Q2 25 | -15.4% | 35.7% | ||
| Q1 25 | -62.2% | 27.9% | ||
| Q4 24 | — | — | ||
| Q3 24 | -57.2% | 25.1% | ||
| Q2 24 | -83.9% | 31.8% | ||
| Q1 24 | 44.3% | 18.8% |
每股收益（稀释后）ESPRREPX
| Q4 25 | $0.32 | $4.02 | ||
| Q3 25 | $-0.16 | $0.77 | ||
| Q2 25 | $-0.06 | $1.44 | ||
| Q1 25 | $-0.21 | $1.36 | ||
| Q4 24 | $-0.14 | $0.52 | ||
| Q3 24 | $-0.15 | $1.21 | ||
| Q2 24 | $-0.33 | $1.59 | ||
| Q1 24 | $0.34 | $0.94 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.9M | — |
| 总债务越低越好 | — | $247.9M |
| 股东权益账面价值 | $-302.0M | $634.2M |
| 总资产 | $465.9M | $1.2B |
| 负债/权益比越低杠杆越低 | — | 0.39× |
8季度趋势，按日历期对齐
现金及短期投资ESPRREPX
| Q4 25 | $167.9M | — | ||
| Q3 25 | $92.4M | — | ||
| Q2 25 | $86.1M | — | ||
| Q1 25 | $114.6M | — | ||
| Q4 24 | $144.8M | — | ||
| Q3 24 | $144.7M | — | ||
| Q2 24 | $189.3M | — | ||
| Q1 24 | $226.6M | — |
总债务ESPRREPX
| Q4 25 | — | $247.9M | ||
| Q3 25 | — | $367.0M | ||
| Q2 25 | — | $275.2M | ||
| Q1 25 | — | $249.3M | ||
| Q4 24 | — | $269.5M | ||
| Q3 24 | — | $288.6M | ||
| Q2 24 | — | $322.7M | ||
| Q1 24 | — | $341.8M |
股东权益ESPRREPX
| Q4 25 | $-302.0M | $634.2M | ||
| Q3 25 | $-451.4M | $566.5M | ||
| Q2 25 | $-433.5M | $556.9M | ||
| Q1 25 | $-426.2M | $532.4M | ||
| Q4 24 | $-388.7M | $510.6M | ||
| Q3 24 | $-370.2M | $507.4M | ||
| Q2 24 | $-344.2M | $489.0M | ||
| Q1 24 | $-294.3M | $434.6M |
总资产ESPRREPX
| Q4 25 | $465.9M | $1.2B | ||
| Q3 25 | $364.0M | $1.2B | ||
| Q2 25 | $347.1M | $1.0B | ||
| Q1 25 | $324.0M | $994.9M | ||
| Q4 24 | $343.8M | $993.5M | ||
| Q3 24 | $314.1M | $997.9M | ||
| Q2 24 | $352.3M | $1.0B | ||
| Q1 24 | $373.1M | $956.4M |
负债/权益比ESPRREPX
| Q4 25 | — | 0.39× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | 0.49× | ||
| Q1 25 | — | 0.47× | ||
| Q4 24 | — | 0.53× | ||
| Q3 24 | — | 0.57× | ||
| Q2 24 | — | 0.66× | ||
| Q1 24 | — | 0.79× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.2M | $64.9M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ESPRREPX
| Q4 25 | $45.2M | $64.9M | ||
| Q3 25 | $-4.3M | $63.6M | ||
| Q2 25 | $-31.4M | $33.6M | ||
| Q1 25 | $-22.6M | $50.4M | ||
| Q4 24 | $-35.0M | $66.4M | ||
| Q3 24 | $-35.3M | $72.1M | ||
| Q2 24 | $-7.2M | $51.6M | ||
| Q1 24 | $53.8M | $56.1M |
自由现金流ESPRREPX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-35.5M | — | ||
| Q2 24 | $-7.3M | — | ||
| Q1 24 | $53.8M | — |
自由现金流率ESPRREPX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -68.7% | — | ||
| Q2 24 | -9.9% | — | ||
| Q1 24 | 39.0% | — |
资本支出强度ESPRREPX
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.1% | — |
现金转化率ESPRREPX
| Q4 25 | — | — | ||
| Q3 25 | — | 3.90× | ||
| Q2 25 | — | 1.10× | ||
| Q1 25 | — | 1.76× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.81× | ||
| Q2 24 | — | 1.54× | ||
| Q1 24 | 0.88× | 2.99× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
REPX
暂无分部数据
